← Back to patent-cliff list
DT-216
Tier C — Watch / tradeDT-216
Design Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FXN
Indications (approved)：Friedreich's ataxia
Regional status
US
Phase I
2022-03-11
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of DT-216?
Approved indications include: Friedreich's ataxia.
When does the DT-216 patent expire?
No public expiry year is available for DT-216 yet; this page updates once verified.
How do I get a quote for DT-216 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30